The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome

Last updated: May 31, 2012
Sponsor: GlaxoSmithKline
Overall Status: Completed

Phase

3

Condition

Williams Syndrome

Dyskinesias

Depression

Treatment

N/A

Clinical Study ID

NCT00357097
RRL106721
  • Ages 18-79
  • All Genders

Study Summary

Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no therapy to know whether a drug could improve both depressive and RLS symptoms.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • diagnosis of idiopathic Restless Legs Syndrome, confirmed by a score of at least 11 onthe RLS Diagnostic Index

  • certain severity of symptoms (at least score of 15 on the International Restless LegsScore (IRLS)

  • Have had RLS symptoms for at least 15 nights in the last four weeks.

  • < 6 hours of sleep in nights with RLS symptoms

  • MADRS (depression rating scale) score of at least 12 (= borderline to depression) atbaseline

Exclusion

Exclusion criteria:

  • any other sleep disorder that might interfere with the RLS symptoms or sleep (e.g.sleep apnea disorder, narcolepsy)

  • Secondary RLS due to diagnosis of renal insufficiency, polyneuropathy, pregnancy (seebelow), iron deficiency anemia

  • Any significant psychiatric disorders (e.g. schizophrenia, bipolar disorder);depression which by judgement of the investigator is caused by RLS, is not anexclusion criterion.

  • Current or past suicidality

  • medication known to trigger/aggravate/ cause or interfere with RLS symptoms (e.g. mostantidepressants, lithium, neuroleptics, opioids, carbidopa, clonidine, antihistamines,anticonvulsants etc.).

  • daytime RLS symptoms which require treatment (daytime: 10 a.m. until 6 p.m.).

  • concomitant movement disorders (e.g. Parkinson's Disease, dyskinesia, dystonia).

  • medical conditions with symptoms which could affect assessments of efficacy (e.g.diabetes, rheumatoid arthritis, fibromyalgia syndrome, cancer etc.).

  • Subjects taking any medication known to induce drowsiness or to affect sleep.

  • Subjects who are pregnant, lactating or of childbearing potential. Women ofchildbearing potential must use adequate contraception

  • clinically significant or unstable medical conditions (e.g. severe heart disease,severe liver or kidney disease etc.).

  • pain syndromes, caused by other disorders than RLS

  • excessive caffeine intake

  • diastolic blood pressure >110mmHg or <50mmHg or systolic blood pressure >180mmHg or <90mmHg at baseline.

  • Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) orthe oral contraceptive pill (OCP) and/or certain drugs which are known to interactwith ropinirole (e.g. ciprofloxacin, cimetidine, tobacco, omeprazole).

Study Design

Total Participants: 240
Study Start date:
June 01, 2006
Estimated Completion Date:
December 31, 2007

Connect with a study center

  • GSK Investigational Site

    Ellwangen, Baden-Wuerttemberg 73479
    Germany

    Site Not Available

  • GSK Investigational Site

    Freiburg, Baden-Wuerttemberg 79104
    Germany

    Site Not Available

  • GSK Investigational Site

    Ostfildern, Baden-Wuerttemberg 73760
    Germany

    Site Not Available

  • GSK Investigational Site

    Ulm, Baden-Wuerttemberg 89081
    Germany

    Site Not Available

  • GSK Investigational Site

    Muenchen, Bayern 80331
    Germany

    Site Not Available

  • GSK Investigational Site

    Nuernberg, Bayern 90403
    Germany

    Site Not Available

  • GSK Investigational Site

    Regensburg, Bayern 93053
    Germany

    Site Not Available

  • GSK Investigational Site

    Unterhaching, Bayern 82008
    Germany

    Site Not Available

  • GSK Investigational Site

    Wuerzburg, Bayern 97070
    Germany

    Site Not Available

  • GSK Investigational Site

    Bad Saarow, Brandenburg 15526
    Germany

    Site Not Available

  • GSK Investigational Site

    Bad Homburg, Hessen 61348
    Germany

    Site Not Available

  • GSK Investigational Site

    Butzbach, Hessen 35510
    Germany

    Site Not Available

  • GSK Investigational Site

    Herborn, Hessen 35745
    Germany

    Site Not Available

  • GSK Investigational Site

    Kassel, Hessen 34128
    Germany

    Site Not Available

  • GSK Investigational Site

    Anklam, Mecklenburg-Vorpommern 17389
    Germany

    Site Not Available

  • GSK Investigational Site

    Schwerin, Mecklenburg-Vorpommern 19053
    Germany

    Site Not Available

  • GSK Investigational Site

    Wismar, Mecklenburg-Vorpommern 23966
    Germany

    Site Not Available

  • GSK Investigational Site

    Achim, Niedersachsen 28832
    Germany

    Site Not Available

  • GSK Investigational Site

    Goettingen, Niedersachsen 37073
    Germany

    Site Not Available

  • GSK Investigational Site

    Hildesheim, Niedersachsen 31134
    Germany

    Site Not Available

  • GSK Investigational Site

    Wolfsburg, Niedersachsen 38440
    Germany

    Site Not Available

  • GSK Investigational Site

    Bielefeld, Nordrhein-Westfalen 33647
    Germany

    Site Not Available

  • GSK Investigational Site

    Bochum, Nordrhein-Westfalen 44809
    Germany

    Site Not Available

  • GSK Investigational Site

    Dueren, Nordrhein-Westfalen 52349
    Germany

    Site Not Available

  • GSK Investigational Site

    Duesseldorf, Nordrhein-Westfalen 40212
    Germany

    Site Not Available

  • GSK Investigational Site

    Gelsenkirchen, Nordrhein-Westfalen 45879
    Germany

    Site Not Available

  • GSK Investigational Site

    Guetersloh, Nordrhein-Westfalen 33330
    Germany

    Site Not Available

  • GSK Investigational Site

    Hattingen, Nordrhein-Westfalen 45525
    Germany

    Site Not Available

  • GSK Investigational Site

    Juelich, Nordrhein-Westfalen 52428
    Germany

    Site Not Available

  • GSK Investigational Site

    Limburgerhof, Rheinland-Pfalz 67117
    Germany

    Site Not Available

  • GSK Investigational Site

    Dresden, Sachsen 01307
    Germany

    Site Not Available

  • GSK Investigational Site

    Halle, Sachsen-Anhalt 06118
    Germany

    Site Not Available

  • GSK Investigational Site

    Koethen, Sachsen-Anhalt 06366
    Germany

    Site Not Available

  • GSK Investigational Site

    Oldenburg, Schleswig-Holstein 26122
    Germany

    Site Not Available

  • GSK Investigational Site

    Gera, Thueringen 07551
    Germany

    Site Not Available

  • GSK Investigational Site

    Jena, Thueringen 07743
    Germany

    Site Not Available

  • GSK Investigational Site

    Berlin, 13156
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.